S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Is Gold Really Boring? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Forecast, Price & News

$2.00
+0.02 (+1.01%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.98
$2.03
50-Day Range
$1.98
$2.27
52-Week Range
$1.85
$3.15
Volume
450,816 shs
Average Volume
566,671 shs
Market Capitalization
$335.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
200.0% Upside
$6.00 Price Target
Short Interest
Bearish
3.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.39 out of 5 stars

Medical Sector

911th out of 961 stocks

Pharmaceutical Preparations Industry

435th out of 455 stocks


ABUS stock logo

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Price History

ABUS Stock News Headlines

3 Stocks to Buy For the COVID Resurgence (ABUS)
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS)
Arbutus ends development of COVID, hepatitis b candidates
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)
JMP Securities Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)
JMP Securities Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Company Calendar

Last Earnings
8/03/2023
Today
9/21/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
96
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+200.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,460,000.00
Net Margins
-309.89%
Pretax Margin
-309.89%

Debt

Sales & Book Value

Annual Sales
$39.02 million
Book Value
$0.91 per share

Miscellaneous

Free Float
158,509,000
Market Cap
$335.12 million
Optionable
Optionable
Beta
2.14

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. William H. Collier (Age 63)
    Pres, CEO & Director
    Comp: $933.01k
  • Mr. Michael J. McElhaugh (Age 49)
    COO & Chief Bus. Officer
    Comp: $606.62k
  • Dr. Michael J. Sofia Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $628.43k
  • Mr. David C. Hastings CPA (Age 62)
    CFO & Chief Accounting Officer
  • Ms. Lisa M. Caperelli
    VP of Investor Relations
  • Mr. J. Christopher Naftzger BA (Age 56)
    Esq., J.D., Gen. Counsel & Chief Compliance Officer
  • Dr. Karen Sims M.D.
    Ph.D., Chief Medical Officer
  • Mr. R. Hector Mackay-Dunn B.A. (Age 72)
    J.D., L.L.B., Q.C, Q.C., Sec.













ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price forecast for 2023?

3 equities research analysts have issued 1-year price objectives for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 200.0% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2023?

Arbutus Biopharma's stock was trading at $2.33 at the beginning of 2023. Since then, ABUS shares have decreased by 14.2% and is now trading at $2.00.
View the best growth stocks for 2023 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company had revenue of $4.65 million for the quarter, compared to analyst estimates of $5.02 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 52.00% and a negative net margin of 309.89%.

What ETFs hold Arbutus Biopharma's stock?

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Direxion mRNA ETF (MSGR) and iShares Genomics Immunology and Healthcare ETF (IDNA).ETFMG Treatments Testing and Advancements ETF (GERM).

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.95%), Whitefort Capital Management LP (4.83%), Rubric Capital Management LP (2.03%), Hudson Bay Capital Management LP (1.70%), Geode Capital Management LLC (1.55%) and Woodline Partners LP (1.47%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.00.

How much money does Arbutus Biopharma make?

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $335.12 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -